Physicians' Academy for Cardiovascular Education

CETP inhibition

Follow the news of this evolving novel class of LDL-c lowering agents

Phase 2 trial with CETP inhibitor combined with ezetimibe meets primary endpoint

News - Jan. 18, 2023

The ROSE2 trial with obecitrapib in combination with ezetimbe as an adjunct to high-intensity statin met its primary endpoint of LDL-c reduction.

A decade of innovation, guidelines, and paradigm shifts in LDL-c management

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.

E-learning CETP inhibitors: Past, present and future

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

What is the rationale for CETP inhibition? Does it have the potential to lower the risk of CHD in addition to high-intensity statin therapy? What have we learned from previous CETP inhibitor outcome trials? and what trials can we expect in the near future? In this series of three presentations, you will be provided with novel insights on CETP inhibition.

LDL-c lowering with CETP inhibitor in patients on high intensity statins

10' education - Oct. 3, 2022 - Prof. Kausik Ray, MD
Prof. Ray presents the results of the ROSE trial, which demonstrated that the CETP inhibitor obicetrapib lowers LDL-c in patients on high intensity statins.

Prof. Ray presents the results of the ROSE trial, which demonstrated that the CETP inhibitor obicetrapib lowers LDL-c in patients on high intensity statins.

What have we learned from previous CETP inhibitor outcome trials?

10' education - Sep. 15, 2022 - Prof. Stephen Nicholls, MD
Prof. Nicholls reviews previous studies with different CETP inhibitors and presents details about ongoing studies with the CETP inhibitor obicetrapib.

Prof. Nicholls reviews previous studies with different CETP inhibitors and presents details about ongoing studies with the CETP inhibitor obicetrapib.

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD

"It has become apparent that the reduction in atherogenic lipoproteins drives CHD protection by CETP inhibition - not changes in HDL-c", says Prof. Kastelein. He explains this statement by findings from studies.

CETP inhibitor reduces LDL-c on top of high-intensity statin

News - May 24, 2022

EAS 2022 Treatment with the CETP inhibitor obicetrapib resulted in a dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

New oral therapy of CETP inhibition for lipid lowering

3' education - May 24, 2022 - Prof. Kausik Ray, MD
Prof. Ray shares the topline results of the ROSE trial, in which the effect of obicetrapib was examined in patients with elevated LDL-c despite high-intensity statin treatment.

EAS 2022 Prof. Ray shares the topline results of the ROSE trial, in which the effect of obicetrapib was examined in patients with elevated LDL-c despite high-intensity statin treatment.

Biology of CETP inhibition

The Biology of CETP inhibition

Slides (curriculum) - Feb. 3, 2022
The Biology of CETP inhibition

Educational slides on the emerging role of CETP inhibition in the management of cardiovascular disease

Larger benefit of CETP inhibitor with longer follow-up

Literature - Dec. 22, 2021 - HPS3/TIMI55-REVEAL Collaborative group - Eur Heart J. 2021

The benefit of the CETP inhibitor anacetrapib on major coronary events increases with longer follow-up, shown in a post-trial analysis of patients who had been randomized to anacetrapib compared to those on placebo in the REVEAL trial.

Dose-dependent reduction of LDL-c levels by CETP-inhibitor

News - Nov. 29, 2021
Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD
There has been confusion about the relationship between HDL-c and CV risk in the past and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

CETP inhibition